Adaptive Biotechnologies initiated with an Outperform, $15 target at Scotiabank

As previously reported, Scotiabank analyst Sung Ji Nam initiated coverage of Adaptive Biotechnologies with an Outperform rating and $15 price target, calling it a "leader" in providing NGS-based minimal residual disease testing for hematological cancers. He highlights Adaptive as "one of the fastest-growing companies in the advanced diagnostics sector," targeting a revenue CAGR of 20%-30% over the next five years.